|
Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America. |
|
|
|
Stock and Other Ownership Interests - Athenex |
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Libbs; Lilly; MSD; Novartis; Roche |
Consulting or Advisory Role - Libbs; Lilly; MSD; Novartis; Roche |
|
|
Honoraria - AstraZeneca; Janssen; Lilly; Novartis; Pfizer; Takeda; Zodiac Pharma |
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Novartis; Pfizer; Takeda; Zodiac Pharma |
Speakers' Bureau - AstraZeneca; Janssen; Lilly; Novartis; Pfizer |
Patents, Royalties, Other Intellectual Property - AstraZeneca; Lilly; Novartis; Pfizer |
|
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Bayer |
|
|
|
|
|
|